Dabigatran Etexilate 110 Mg Side Effects

Tell your doctor if you have any side effect that bothers you or does not go away.

Dabigatran etexilate 110 mg side effects. Some side effects may occur that usually do not need medical attention. Blood in the urine. 110 mg orally 1 4 hours after surgery and after hemostasis has been achieved on first day then 220 mg taken once day for 28 35 days if dabigatran is not started on the day of surgery after hemostasis has been achieved initiate treatment with 220 mg once day. For more information ask your doctor or pharmacist and be sure to also access the medication guide.

Exposure to dabigatran increases with the severity of renal impairment. Talk with your doctor if you have recently had or will be having a spinal or epidural procedure. Common side effects of pradaxa include. A very serious allergic reaction to this drug is rare.

Rash itching swelling. Crcl greater than 30 ml minute. A very serious allergic reaction to this drug is rare. These are not all of the possible side effects of pradaxa.

Unusual bleeding or bruising. Large hive like swelling on the face eyelids lips tongue throat hands legs feet or sex organs. Call your doctor right away if you have any signs of nerve problems like back pain numbness or tingling muscle weakness paralysis or loss of bladder or bowel control. Indigestion upset stomach or burning.

Bleeding see warnings and precautions 5 2. Side effects of pradaxa include. Auc increases 1 5 3 2 and 6 3 times in patients with mild crcl 50 to 80 ml minute moderate crcl 30 to 50 ml minute and severe crcl 15 to 30 ml minute renal impairment respectively. Bleeding is the most serious side effect reported with dabigatran.

Pinpoint red spots on the skin. Major or severe bleeding may occur and regardless of location may lead to disabling life threatening or even fatal outcomes. Rash itching swelling. Bruising and minor bleeding such as nosebleeds and bleeding from cuts nausea abdominal or stomach pain stomach upset indigestion heartburn diarrhea skin rash or.